INmune Bio Net Debt Over Time
| INMB Stock | USD 4.88 0.08 1.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out INmune Bio Performance and INmune Bio Correlation. INmune |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Debt Analysis
Compare INmune Bio and related stocks such as Tff Pharmaceuticals, Anebulo Pharmaceuticals, and Abcam PLC Net Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TFFP | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (28.1 M) | (35.3 M) | (33.8 M) | (16.4 M) | (5.4 M) | (5.6 M) |
| ANEB | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (20 M) | (14.5 M) | (11.2 M) | (3.1 M) | (3.2 M) |
| ANTX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.1 M) | (12.1 M) | (27.2 M) | (15.6 M) | (16.4 M) |
| CUE | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (14.9 M) | (61 M) | (20.8 M) | (38.5 M) | (67.7 M) | (54.3 M) | (32.3 M) | (33.8 M) | (35.5 M) |
| ANIX | (2.8 M) | (307.4 K) | 4.7 M | (3.4 M) | (4.4 M) | 1.7 M | (3.3 M) | (3.1 M) | (3.5 M) | (6.4 M) | (28.9 M) | (12.1 M) | (740 K) | (666 K) | (699.3 K) |
| INAB | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (610 K) | (17.8 M) | (34.6 M) | (12.3 M) | (16.4 M) | (17.2 M) |
| PYPD | (977 K) | (977 K) | (977 K) | (1.3 M) | (1.5 M) | (1.5 M) | (10.2 M) | (3.9 M) | (7.3 M) | (3.9 M) | (4.3 M) | (9.8 M) | 5.2 M | 6.2 M | 6.5 M |
| AVTE | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (4.6 M) | (53.6 M) | (21.3 M) | (22.8 M) | (24 M) |
| AVXL | (28.1 K) | 287.6 K | (134.2 K) | (1.4 M) | (15.2 M) | (9.2 M) | (27.4 M) | (22.9 M) | (22.2 M) | (29.2 M) | (152.1 M) | (149.2 M) | (151 M) | (135.9 M) | (129.1 M) |
| SAVA | (9.3 M) | (73.1 M) | (56.3 M) | (49.8 M) | (40.6 M) | (31.3 M) | (18.7 M) | (10.5 M) | (19.8 M) | (23 M) | (93.2 M) | (233.2 M) | (200.9 M) | (121.1 M) | (115.1 M) |
| BIVI | (505.7 K) | (505.7 K) | (505.7 K) | (332.9 K) | (267.5 K) | (113.8 K) | 29.9 K | 780.1 K | (339.9 K) | 873.8 K | (4.5 M) | (6.4 M) | (5 M) | (17.7 M) | (16.8 M) |
| CGTX | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 7.7 M | (54.7 M) | (40.1 M) | (28.7 M) | (30.1 M) |
| TCRX | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (27.4 M) | (155.4 M) | (34 M) | (40.9 M) | (43 M) |
| DRMA | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | (708.1 K) | 3 M | (10.8 M) | (6.2 M) | (7.4 M) | (7.1 M) |
INmune Bio and related stocks such as Tff Pharmaceuticals, Anebulo Pharmaceuticals, and Abcam PLC Net Debt description
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.My Equities
My Current Equities and Potential Positions
| INmune Bio | INMB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.88
Check out INmune Bio Performance and INmune Bio Correlation. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.